An Updated Review on Pancreatic Cancer: Advancement, Diagnosis and Treatment

Read full text Summarise with VIRAT
Authors: Falgun Mehta, Deep Parekh, Aagam Shah, Heer Patel, Dev Gandhi, Dhavan Kothari, Deep Parekh, Aagam Shah, Heer Patel, Dev Gandhi, Dhavan Kothari
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This comprehensive review on pancreatic cancer (PC), particularly Pancreatic Ductal Adenocarcinoma (PDAC), examines its rising global incidence and lethality (5-year survival rate \sim 11.5\%) by detailing its anatomy, pathology, diagnosis, and modern treatment. PDAC is strongly linked to modifiable risk factors like smoking, chronic pancreatitis, and diabetes, and is genetically driven by mutations in KRAS (over 90\% of cases) and tumor suppressors like TP53 and SMAD4. Diagnosis often occurs late due to non-specific symptoms, relying primarily on MDCT and EUS-FNA, supplemented by the evolving CA19-9 marker and newer liquid biopsy technologies like the PAC-MANN test. While surgical resection (e.g., the Whipple procedure) remains the only curative option, most patients require systemic therapy, with FOLFIRINOX being the highly effective but toxic mainstay for metastatic disease. The trend is shifting towards neoadjuvant chemotherapy to downstage tumors and precision oncology, highlighted by the success of PARP inhibitors for BRCA1/2-mutated tumors and emerging KRAS-targeted therapies, offering hope for improved stage-dependent prognoses.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Pancreatitis Pathology and Treatment Cholangiocarcinoma and Gallbladder Cancer Studies

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
30 March 2026
Language
EN